JustinFGainorMD

PubMed

• Current opportunities and challenges in ALK-positive lung cancer.
  Lin, J., Gainor, J.> ;Translational Lung Cancer Research. 2024 Jan 31
• Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
  Subbiah, V., Hu, M., Mansfield, A., Taylor, M., Schuler, M., Zhu, V., Hadoux, J., Curigliano, G., Wirth, L., Gainor, J., Alonso, G., Adkins, D., Godbert, Y., Ahn, M., ...> ;Thyroid. 2024 Jan 1
• Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution.
  Jaime L Schneider, Khvaramze Shaverdashvili, Mari Mino-Kenudson, Subba R Digumarthy, Andrew Do, Audrey Liu, Justin F Gainor, Jochen K Lennerz, Timothy F Burns, Jessica...> ;NPJ Precision Oncology. 2023 Nov 3
• 3 citations
  Efficacy and Tolerability of/Combinations in Patients With-Rearranged Lung Cancer With AcquiredAmplification: A Retrospective Analysis.
  Ibiayi Dagogo-Jack, Lesli A Kiedrowski, Rebecca S Heist, Jessica J Lin, Catherine B Meador, Elizabeth A Krueger, Andrew Do, Jennifer Peterson, Lecia V Sequist, Justin ...> ;JTO Clinical and Research Reports. 2023 Aug 1
• 16 citations
  Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
  Hideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, Naveed Nikpour, Marcello Stanzione, Sunwoo Oh, Adam Langenbucher, Susanna Monroe, Wenjia Su, Heidie Frisco Cabanos, Far...> ;Nature. 2023 Aug 1
• 8 citations
  MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.
  Yu Qian, Ana Galan-Cobo, Irene Guijarro, Minghao Dang, David Molkentine, Alissa Poteete, Fahao Zhang, Qi Wang, Jing Wang, Edwin Parra, Apekshya Panda, Jacy Fang, Ferdi...> ;Cancer Cell. 2023 Jul 10
• 9 citations
  Immune Checkpoint Inhibitors - The Need for Innovation.
  P Connor Johnson, Justin F Gainor, Ryan J Sullivan, Dan L Longo, Bruce Chabner> ;The New England Journal of Medicine. 2023 Apr 20
• Letter to the Editor Reply: Kleebayoon et al.
  Catherine B Meador, Justin F Gainor> ;Clinical Lung Cancer. 2023 Jul 1
• First-line lorlatinib for advanced ALK-positive non-small-cell lung cancer.
  Jessica J Lin, Justin F Gainor> ;The Lancet. Respiratory Medicine. 2023 Apr 1
• 7 citations
  Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.
  H Borghaei, T-E Ciuleanu, J-S Lee, A Pluzanski, R Bernabe Caro, M Gutierrez, Y Ohe, M Nishio, J Goldman, N Ready, D R Spigel, S S Ramalingam, L G Paz-Ares, J F Gainor,...> ;Annals of Oncology. 2023 Feb 1
• 9 citations
  Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies.
  Ibiayi Dagogo-Jack, Antonello Abbattista, Stan Krulewicz, Andrew Do, Jennifer Peterson, Jessica J Lin, Justin F Gainor, Rossella Messina, Elizabeth A Krueger, Holger T...> ;Journal of Thoracic Oncology. 2023 Jan 1
• 1 citations
  Selective Targeting of RET Fusions in Lung Cancer.
  Jessica J Lin, Justin F Gainor> ;Journal of Clinical Oncology. 2023 Jan 10
• 3 citations
  Clinicopathologic Characteristics and Outcomes for Patients WithG12D-Mutant NSCLC.
  Alona Muzikansky, Jochen Lennerz, Farhaana Narinesingh, Mari Mino-Kenudson, Yin P Hung, Zofia Piotrowska, Ibiayi Dagogo-Jack, Lecia V Sequist, Justin F Gainor, Jessica...> ;JTO Clinical and Research Reports. 2022 Sep 1
• 7 citations
  High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities.
  Whijae Roh, Yifat Geffen, Hongui Cha, Mendy Miller, Shankara Anand, Jaegil Kim, David I Heiman, Justin F Gainor, Peter W Laird, Andrew D Cherniack, Chan-Young Ock, Se-...> ;Cancer Research. 2022 Nov 2
• 9 citations
  Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.
  Luis G Paz-Ares, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong-Seok Lee, Justin F Gainor, Gregory A Otterson, Clarisse Audigier-Valette, Neal Ready, Michael Schenker, He...> ;Journal of Thoracic Oncology. 2023 Jan 1
• 42 citations
  Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
  F Griesinger, G Curigliano, M Thomas, V Subbiah, C S Baik, D S W Tan, D H Lee, D Misch, E Garralda, D-W Kim, A J van der Wekken, J F Gainor, L Paz-Ares, S V Liu, G P K...> ;Annals of Oncology. 2022 Nov 1
• 36 citations
  Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.
  Joshua K Sabari, Vamsidhar Velcheti, Kazuhide Shimizu, Matthew R Strickland, Rebecca S Heist, Mohini Singh, Naema Nayyar, Anita Giobbie-Hurder, Subba R Digumarthy, Jus...> ;Clinical Cancer Research. 2022 Aug 2
• 14 citations
  Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy.
  Or Kalchiem-Dekel, Christina J Falcon, Christine M Bestvina, Dazhi Liu, Lauren A Kaplanis, Clare Wilhelm, Jordan Eichholz, Guilherme Harada, Lori J Wirth, Subba R Digu...> ;Journal of Thoracic Oncology. 2022 Sep 1
• 10 citations
  Lung-RADS Category 3 and 4 Nodules on Lung Cancer Screening in Clinical Practice.
  Milena Petranovic, Avik Som, Markus Y Wu, Esther Y Park, Eric W Zhang, John M Archer, Shaunagh McDermott, Melin Khandekar, Michael Lanuti, Justin F Gainor, Inga T Lenn...> ;AJR. American Journal of Roentgenology. 2022 Jul 1
• 3 citations
  A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib.
  Jaime L Schneider, Alona Muzikansky, Jessica J Lin, Elizabeth A Krueger, Inga T Lennes, Joseph O Jacobson, Michael Cheng, Rebecca S Heist, Zofia Piotrowska, Justin F G...> ;JTO Clinical and Research Reports. 2022 Jul 1
• 12 citations
  ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study.
  Melissa Johnson, Arkadiusz Z Dudek, Ammar Sukari, Justin Call, Paul R Kunk, Karl Lewis, Justin F Gainor, John Sarantopoulos, Patrice Lee, Adele Golden, Allison Harney,...> ;Clinical Cancer Research. 2022 Jun 13
• 8 citations
  Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions.
  Schad, S., Chow, A., Mangarin, L., Pan, H., Zhang, J., Ceglia, N., Caushi, J., Malandro, N., Zappasodi, R., Gigoux, M., Hirschhorn, D., Budhu, S., Amisaki, M., Arniell...> ;The Journal of Experimental Medicine. 2022 Jun 6
• 19 citations
  Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.
  Aya Shiba-Ishii, Ted W Johnson, Ibiayi Dagogo-Jack, Mari Mino-Kenudson, Theodore R Johnson, Ping Wei, Scott L Weinrich, Michele A McTigue, Makeba A Walcott, Linh Nguye...> ;Nature Cancer. 2022 Jun 1
• 44 citations
  Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer.
  Miguel Lopez de Rodas, Venkata Nagineni, Arvind Ravi, Ila J Datar, Mari Mino-Kenudson, German Corredor, Cristian Barrera, Lindsey Behlman, David L Rimm, Roy S Herbst, ...> ;Journal for Immunotherapy of Cancer. 2022 Jun 1
• 2 citations
  Searching for Synergy: Chemotherapy and Checkpoint Inhibitors.
  Diane Tseng, Justin F Gainor> ;Clinical Cancer Research. 2022 Jun 1
• Join now to see all

Journal Articles

• Differential Expression of PD-L1 and IDO1 in Association with the Immune Microenvironment in Resected Lung Adenocarcinomas  
  M Lisa Zhang, Justin F Gainor, Meghan J Mooradian, Nature
• Oxford University Press Has Registered This DOI Pre-Publication  
  R S Heist, Z Piotrowska, C G Azzoli, A T Shaw, I T Lennes, L V Sequist, J F Gainor, Oxford University Press

Abstracts/Posters

• A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma
  Justin Gainor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSC... 
  2019 ASCO Annual Meeting - 6/1/2019
• Response and durability of anti-PD-(L)1 therapy in never- or light-smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression. Immunotherapy for Oncogen... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018